Pharming Group N.V. filed a Form 6-K on November 6, 2026, announcing that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved an extension of the marketing authorization for Joenja (leniolisib) to include children aged 4 to 11 years weighing at least 27 kg with activated PI3K delta syndrome (APDS).

Key Highlights

  • First pediatric approval in the U.K.: Joenja is now the first treatment approved in the U.K. specifically for children with APDS, according to the filing.
  • Eligible patient criteria: The expanded indication covers children aged 4 to 11 years who weigh at least 27 kg, with approved dosing of 40 mg and 50 mg twice daily.
  • Prior U.K. indication: Joenja was previously authorized in the U.K. for eligible adults and adolescents aged 12 years and older.
  • Expected availability: Joenja is expected to become available to patients covered by the expanded indication in February 2027, the filing stated.
  • Regulatory basis: The MHRA decision was supported by data from Pharming's pediatric clinical program conducted under an MHRA-agreed Pediatric Investigation Plan (PIP) for leniolisib.
  • Tolerability finding: The filing noted that leniolisib "was generally well-tolerated in patients of 4 years and above, supporting a positive benefit: risk profile in this age group."

MHRA Extends Joenja Authorization to Younger Children With APDS in the U.K.

Pharming Group N.V. (Euronext Amsterdam: PHARM/NASDAQ:PHAR) disclosed that the MHRA has approved the extension of Joenja's marketing authorization in the U.K. to children aged 4 to 11 years who weigh at least 27 kg and have APDS, a rare primary immunodeficiency. The approved dosing for eligible pediatric patients in this weight group is 40 mg and 50 mg twice daily, according to the filing. The company stated that Joenja is the first treatment approved in the U.K. specifically for children with APDS.

The filing noted that the MHRA decision was supported by data from Pharming's pediatric clinical program, carried out under an MHRA-agreed Pediatric Investigation Plan (PIP) for leniolisib, together with additional clinical pharmacology and safety assessments. Pharming disclosed it "will work closely with the NHS and relevant stakeholders to support timely access for eligible patients," with availability under the expanded indication expected in February 2027.

According to the filing, APDS is caused by variants in either the PIK3CD or PIK3R1 genes and is characterized by severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy. The filing cited published reports that people with APDS frequently experience misdiagnosis and "a median 7-year diagnostic delay." The disease affects approximately 1 to 2 people per million worldwide, according to the filing. Pharming described the MHRA approval as "another step in Pharming's strategy to expand Joenja across age groups and international markets."

What Was Disclosed

Pharming Group filed a Form 6-K reporting MHRA approval of an expanded U.K. marketing authorization for Joenja (leniolisib) covering children aged 4 to 11 years weighing at least 27 kg with APDS, with patient availability expected in February 2027.